XML 42 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Organization and Summary of Significant Accounting Policies - Narrative (Details)
6 Months Ended
Sep. 30, 2021
USD ($)
segment
shares
Oct. 26, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of operating segments | segment 1  
Number of reporting segments | segment 1  
Cash, cash equivalents and marketable securities $ 616,000,000  
Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Number of shares owned (in shares) | shares 50,041,181  
Ownership percentage 53.80%  
Sumitomo Dainippon Pharma Co., Ltd. | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Term Loan | Majority Shareholder    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Available borrowing capacity $ 41,300,000  
Pfizer | Subsequent Event    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Outstanding payment from milestones achieved   $ 3,600,000,000
Richter | Subsequent Event    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Outstanding payment from milestones achieved   $ 122,500,000